|
KMID : 1146920200500030295
|
|
Journal of Pharmaceutical Investigation
2020 Volume.50 No. 3 p.295 ~ p.307
|
|
|
Recent advances in the formulation of sphingolipid anticancer therapeutics
|
|
Choi Min-Koo
Song Im-Sook
|
|
|
Abstract
|
|
|
Background: The bioactive sphingolipids such as ceramide, sphingosine, and sphingosine-1-phosphate are of special interest as key regulators of cellular proliferation or apoptosis signaling. The balance between ceramide and sphingosine-1-phosphate is critical for the selection of proliferative or apoptotic signaling as well as for therapeutic efficacy against cancer cells.
Area covered: A number of drug candidates designed to regulate the balance between ceramide and sphingosine-1-phosphate have been developed and several (i.e., safingol, ABC294640, Sonepcizumab, and fingolimod) are under clinical investigation as anti-cancer drugs. Various nanotherapeutic challenges combined with the use of anticancer drugs and/or phospholipid metabolism inhibitors and short chain ceramide has been investigated to increase the cellular accumulation of ceramide, which acts as apoptotic signaling molecules.
Expert opinion: Many sphingolipid-containing nanotherapeutics have shown promising results as cancer treatments. These sphingolipid nanotherapeutics can include a synergistic combination of short chain ceramide and ceramide-forming anticancer agents or sphingolipid metabolism inhibitors. Sphingolipid nanotherapeutics could also be used to treat multidrug-resistant cancer cells as well as sensitive cancer cells.
|
|
|
KEYWORD
|
|
|
Sphingolipids, Ceramide, Cancer, Sphingoliposome, Nanotherapeutics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|